The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1517
Nusinersen (Spinraza) for Spinal Muscular Atrophy
The full article is available to subscribers Subscriber Login   

The FDA has approved nusinersen (Spinraza – Biogen) for treatment of spinal muscular atrophy (SMA), a hereditary neurodegenerative disease that occurs in about one in every 10,000 births.1 It is the first drug to be approved in the US for this indication.

SPINAL MUSCULAR ATROPHY — SMA is an autosomal recessive neuromuscular disorder in which degeneration of alpha motor neurons in the anterior horn cells of the spinal cord leads to muscle weakness and atrophy. Most cases are caused by a homozygous deletion or mutation in the 5q13 survival of motor neuron 1 (SMN1) gene, which leads to SMN protein deficiency. Mutations in a similar gene, SMN2, are correlated with a milder SMA phenotype.2

SMA is classified based on the age of symptom onset and motor function achieved. Infants with type 1 SMA (age of onset 0-6 months) are unable ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Nusinersen (Spinraza) for Spinal Muscular Atrophy
Article code: 1517b
 Electronic, downloadable article - $25